3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2/3
1
Phase 2
1
Status
Recruiting
2
Active not recruiting
2
Sponsor Class
OTHER
4
INDUSTRY
4
NETWORK
1
Study Type
Interventional
4
Sponsor
Cancer Type
Thoracic
4
Conditions
Carcinoma, Non-Small-Cell Lung
3
Non Small Cell Lung Carcinoma NSCLC
1
Lung Neoplasms
1
Interventions
pembrolizumab
282
Carboplatin
217
Cisplatin
147
Gemcitabine
146
Paclitaxel
142
Bevacizumab
116
Pemetrexed
114
Docetaxel
101
Oxaliplatin
79
durvalumab
78
Dexamethasone
77
Fluorouracil
76
atezolizumab
75
Nivolumab
75
Cyclophosphamide
74
130-nm albumin-bound paclitaxel
71
Fulvestrant
70
Capecitabine
64
Cetuximab
63
Injections
62
Leucovorin
60
Rituximab
55
fludarabine
50
Lenalidomide
50
venetoclax
44
Prednisone
43
Irinotecan
42
Letrozole
40
enzalutamide
39
tislelizumab
38
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
INDUSTRY
×
CP protocol
×
90 days
×
Clear all
NCT05061550
2026-05-22
NeoCOAST-2
AstraZeneca
Phase 2
Recruiting
630 enrolled
NCT07365319
2026-05-20
TeLuRide-008
Eikon Therapeutics
Phase 2/3
Recruiting
750 enrolled
NCT02453282
2026-05-12
MYSTIC
AstraZeneca
Phase 3
Active not recruiting
1,118 enrolled
40 charts
NCT02542293
2026-05-01
NEPTUNE
AstraZeneca
Phase 3
Active not recruiting
953 enrolled
29 charts